Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Antihistamine use may improve oncologic and survival outcomes in patients receiving second-line atezolizumab for advanced or metastatic urothelial carcinoma, according to research published in ...

Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...

Vetigenics, a clinical-stage animal health biotechnology company specializing in antibody therapeutics for pets, announces ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

ALX Oncology Holdings Inc.’s ALXO share price has surged by 11.88%, which has investors questioning if this is right time to ...

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will particip ...